Dr. Mayu Yoshikawa joined ARCH Venture Partners as a Venture Partner in 2025, focusing on company creation and business development leveraging innovations from Japanese academia. She is an experienced biotech investor and company builder with deep connections in Japan’s academic and startup communities, dedicated to bridging cutting-edge science from Japan into global ventures.
Dr. Yoshikawa launched her career at McKinsey & Company and subsequently spent six years leading biotech investments at a venture capital firm in Japan. She also served as a Program Promoter at the Japan Science and Technology Agency (JST), working to advance academic research toward commercialization. She played a key role supporting the formation of AN Ventures, a Japan–U.S. biotech fund dedicated to building blockbuster biotech companies leveraging science from Japan.
Previously, Dr. Yoshikawa served as a Senior Advisor at ARCH, where she was deeply involved in supporting multiple cross-border biotech startups between Japan and the U.S., including City Therapeutics. Leveraging her deep networks within Japanese academia and innovation ecosystems, she has been instrumental in guiding these ventures from inception through growth. Her expertise spans cross-border company formation, biotech investing, and academic technology commercialization. Her Japanese background and experience uniquely position her to bridge scientific innovation between Japan and the United States.
Dr. Yoshikawa holds a Ph.D. in Life Sciences from the University of Tokyo’s Graduate School of Frontier Sciences.